Expression of biliary antigen and its clinical significance in hepatocellular carcinoma

被引:18
|
作者
Yoon, DS
Jeong, J
Park, YN
Kim, KS
Kwon, SW
Chi, HS
Park, C
Kim, BR
机构
[1] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea
[3] Kwandong Univ, Coll Med, Dept Surg, Kangnung, South Korea
[4] Pochon CHA Univ, Coll Med, Dept Surg, Kyungkido, South Korea
关键词
hepatocellular carcinoma; biliary antigen; clinical significance;
D O I
10.3349/ymj.1999.40.5.472
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In order to classify the hepatocellular carcinomas (HCCs) which had diverse clinicopathologic characteristics, we divided HCCs into two groups according to the expression of biliary antigen on the basis of the hypothesis that the hepatocyte and biliary epithelial cell originate from the same precursor cell, and then we investigated the clinical and pathologic characteristics in the two groups. Forty HCC cases with no preoperative treatment and at least two-year follow-up data were selected among 202 cases of HCC files from 1991 to 1995. Expression of biliary antigen (AE1, cytokeratin 19), p53, AFP, and Ki-67 in the tumor tissue were assessed by immunohistochemistry. Positive cytokeratin 19 was noted in one case (2.5%); AE1 was detected in 40% of patients; p53 was overexpressed in 20% of patients; and AFP was detected in 45% of patients. No statistical difference between the biliary antigen positive group (16 cases) and the negative group (24 cases) were noted in terms of mean age, sex, presurgical serum AFP level, Child class, and tumor size. HBsAg positive race was 66.7% for the biliary antigen (-) group and 93.8% for the biliary antigen (+) group with a statistically significant difference (p=0.048). The number of cases for Edmonson-Steiner grade I/II and III/IV were 15 and 9 in the biliary antigen (-) group, and 4 and 12 in the biliary antigen (+) group, respectively, with a statistically significant difference (p=0.024). The 1, 3 and 5-year disease-free survival races were 69.7, 40.9 and 40.9% for the biliary antigen (-) group and 73.7, 39.1, 39.1% for the biliary antigen (+) group with no statistically significant difference. The 1, 3 and 5-year overall survival rates were 91.7, 73.8, 66.4% for the biliary antigen (-) group and 68.8, 34.4, 34.4% for the biliary antigen (+) group, with a significantly greater overall survival rate for the biliary antigen negative group (p=0.045). Poor histopathological differentiation, a high HBsAg positive rate and poor overall survival rate were noted in the biliary antigen positive group and the differences were statistically significant. In conclusion, HCCs with positive biliary antigen, which originates from more primitive cells, is suggested to he more aggressive than HCCs with negative biliary antigen.
引用
收藏
页码:472 / 477
页数:6
相关论文
共 50 条
  • [31] Expression and Clinical Significance of MPS-1 in Hepatocellular Carcinoma
    Jiang, He
    Yuan, Feifei
    Zhao, Zhiying
    Xue, Tongchun
    Ge, Ningling
    Ren, Zhenggang
    Zhang, Lan
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 9145 - 9152
  • [32] Clinical significance of miRNA-433 expression in hepatocellular carcinoma
    Li, Zhanzhan
    Li, Yanyan
    Xue, Jing
    BIOMEDICAL RESEARCH-INDIA, 2017, 28 (17): : 7661 - 7664
  • [33] Expression and clinical significance of Nectin-4 in hepatocellular carcinoma
    Ma, Jie
    Sheng, ZhiYong
    Lv, Yang
    Liu, WenBin
    Yao, QiYang
    Pan, TingTing
    Xu, ZhiJun
    Zhang, ChuanHai
    Xu, GeLiang
    ONCOTARGETS AND THERAPY, 2016, 9 : 183 - 190
  • [34] Expression and Clinical Significance of YAP, TAZ, and AREG in Hepatocellular Carcinoma
    Han, Su-xia
    Bai, E.
    Jin, Gui-hua
    He, Chen-chen
    Guo, Xi-jing
    Wang, Li-juan
    Li, Meng
    Ying, Xia
    Zhu, Qing
    JOURNAL OF IMMUNOLOGY RESEARCH, 2014, 2014
  • [35] Expression and clinical significance of NLRC5 in hepatocellular carcinoma
    Ma, Xiangyu
    Ning, Shangkun
    Sun, Tong
    Liu, Mei
    Liu, Jibing
    CANCER BIOLOGY & THERAPY, 2024, 25 (01)
  • [36] Expression and clinical significance of miR-3615 in hepatocellular carcinoma
    Yuan, Xin
    Zhang, Yize
    Yu, Zujiang
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2021, 49 (01)
  • [37] Clinical significance of microRNA-155 expression in hepatocellular carcinoma
    Guan, Chengnong
    Yang, Feng
    He, Xichun
    Li, Tuhua
    Yang, Qingmei
    He, Huiping
    Xu, Meng
    ONCOLOGY LETTERS, 2016, 11 (02) : 1574 - 1580
  • [38] Clinical Significance of ABC Transporter Expression in Patients with Hepatocellular Carcinoma
    Fan, Li-xin
    Zhang, Yong
    Zhou, Yi
    Wang, Zhi-dong
    Zhang, Yong-mei
    Chen, Hai-long
    JOURNAL OF HARD TISSUE BIOLOGY, 2016, 25 (01) : 81 - 87
  • [39] Expression and clinical significance of CMTM1 in hepatocellular carcinoma
    Song, Xin
    Zhang, Shidong
    Tian, Run
    Zheng, Chuanjun
    Xu, Yuge
    Wang, Tianxian
    Bei, Chunhua
    Zhang, Huixia
    He, Xiao
    Zhu, Xiaonian
    Tan, Shengkui
    OPEN MEDICINE, 2021, 16 (01): : 217 - 223
  • [40] Expression and Clinical Significance of CMTM6 in Hepatocellular Carcinoma
    Zhu, Xiaonian
    Qi, Guangzi
    Li, Cong
    Bei, Chunhua
    Tan, Chao
    Zhang, Ying
    Shi, Wenxiang
    Zeng, Wen
    Kong, Juan
    Fu, Yuanyuan
    Tan, Shengkui
    DNA AND CELL BIOLOGY, 2019, 38 (02) : 193 - 197